BACKGROUND Bilastine is a novel nonsedative H(1)-receptor antagonist, which may be used for the symptomatic treatment of chronic idiopathic urticaria (CU). The aim of this study was to compare the clinical efficacy and safety of bilastine 20 mg vs levocetirizine 5 mg and placebo in CU patients with moderate-to-severe symptoms. METHODS Overall 525 male and female subjects aged 18-70 years were...

For the past one decade, there has been an enhanced demand for more patient-friendly and compliant dosage forms. As a result, the demand for developing new technologies has been increasing annually. Orally disintegrating films (ODF) have carved a niche amongst the oral drug delivery systems due to their high patient compliance[1-3]. United States Food and Drug Administration (USFDA) defined the...

Competition experiments with [H]mepyramine showed that cetirizine and its enantiomers, levocetirizine and (S)-cetirizine, bound with high affinity and stereoselectivity to human H1 histamine receptors (Ki values of 6, 3, and 100 nM, respectively). Cetirizine and levocetirizine were 600-fold more selective for H1 receptors compared with a panel of receptors and channels. Binding results indicate...

and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, pleas...

413 Indian Journal of Dermatology 2014; 59(4) the patient may have taken, or due to the coloring agent titanium dioxide present in the tablet of levocetirizine. However, detailed history taking excluded possibility of both, as there was no other drug intake during last 4 weeks. Also, the patient did not develop any reaction on provocation with fexofenadine, which contained titanium dioxide. The...

in healthy volunteers. Levocetirizine reduces plasmatic level of IL-6 (1.19 versus 1.006, P 1⁄4 0.0097) and IL-8 (8.90 versus 6.90, P 1⁄4 0.0003) after 4 weeks treatment, while Desloratadine has influence only IL-6 level (1.68 versus 1.36, P 1⁄4 0.0038). The intergroup analysis revealed no significant difference between these 2 drugs regarding IL-6 (P 1⁄4 0.36) and IL-8 (P 1⁄4 0.25). Conclusion...